Clinical Trials Logo

Migraine Prophylaxis clinical trials

View clinical trials related to Migraine Prophylaxis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05846373 Recruiting - Clinical trials for Migraine Prophylaxis

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Start date: November 25, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective single center, randomized, double-blind, 3 arm placebo-controlled study in subjects with migraine headache requiring prophylactic treatment. The patients will be randomized to receive Nicotinic Acid Extended-release tablet 500 mg or 1000 mg or placebo for 12 weeks. The safety and efficacy outcome measures will be assessed at baseline and 12 weeks.